Tether Invests $200M in Blackrock Neurotech: A Game-Changer in Brain-Computer Interface Technology
April 30, 2024, 3:32 pm
Tether, the stablecoin giant, has made a bold move by investing $200 million in Blackrock Neurotech, a Salt Lake City-based brain-computer interface startup. This investment marks a significant milestone in the field of BCI technology, where human potential meets technological innovation.
Blackrock Neurotech, founded in 2008 by Dr. Florian Solzbacher and Marcus Gerhardt, is on a mission to revolutionize healthcare and restore function in individuals suffering from paralysis, lost function, and neurological disorders. Their precision electrode technology has already been applied to over 40 individuals, enabling them to see, hear, feel, and move again.
With Tether's investment, Blackrock Neurotech aims to commercialize and roll out its medical solutions to a wider audience, while also boosting its research and development efforts. This partnership signifies a shared vision between the two companies to push the boundaries of what's possible at the intersection of technology and human potential.
Paolo Ardoino, CEO of Tether, expressed his excitement about the investment, stating that Blackrock Neurotech is just the beginning of their journey through Tether Evo, a division dedicated to advancing humanity through innovative projects. The potential of BCI technology to enhance communication, rehabilitation, and cognitive abilities is immense, and Tether is committed to supporting emerging technologies with transformative capabilities.
As the world of brain-computer interface technology continues to evolve, with companies like Neuralink making headlines, Tether's investment in Blackrock Neurotech signals a growing interest in investing in innovation that has the power to shape the future of healthcare and human capabilities. This partnership is a testament to the potential of BCI technology to open new realms of possibilities and redefine the way we interact with technology and each other.
Blackrock Neurotech, founded in 2008 by Dr. Florian Solzbacher and Marcus Gerhardt, is on a mission to revolutionize healthcare and restore function in individuals suffering from paralysis, lost function, and neurological disorders. Their precision electrode technology has already been applied to over 40 individuals, enabling them to see, hear, feel, and move again.
With Tether's investment, Blackrock Neurotech aims to commercialize and roll out its medical solutions to a wider audience, while also boosting its research and development efforts. This partnership signifies a shared vision between the two companies to push the boundaries of what's possible at the intersection of technology and human potential.
Paolo Ardoino, CEO of Tether, expressed his excitement about the investment, stating that Blackrock Neurotech is just the beginning of their journey through Tether Evo, a division dedicated to advancing humanity through innovative projects. The potential of BCI technology to enhance communication, rehabilitation, and cognitive abilities is immense, and Tether is committed to supporting emerging technologies with transformative capabilities.
As the world of brain-computer interface technology continues to evolve, with companies like Neuralink making headlines, Tether's investment in Blackrock Neurotech signals a growing interest in investing in innovation that has the power to shape the future of healthcare and human capabilities. This partnership is a testament to the potential of BCI technology to open new realms of possibilities and redefine the way we interact with technology and each other.